Cross-source evidence timeline

Terlipressin research timeline

Follow 63 selected, directly cited source records from March 9, 2006 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

63Selected records
15Source years
3Evidence lanes
November 9, 2026Latest source date

Source year

2026

17 records
  1. Literature metadata

    A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.↗

    PubMed lists PMID 38526204 in The American journal of gastroenterology as Journal Article, Randomized Controlled Trial, Equivalence Trial, Comparative Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review.↗

    PubMed lists PMID 41204083 in BMC anesthesiology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT06108362↗

    PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07252401↗

    PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  5. Literature metadata

    From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.↗

    PubMed lists PMID 38353565 in Hepatology (Baltimore, Md.) as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-02-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).↗

    PubMed lists PMID 41711944 in Pediatric nephrology (Berlin, Germany) as Journal Article, Review, with publication-date metadata of 2026-02-19 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].↗

    PubMed lists PMID 31941255 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Review, with publication-date metadata of 2019-12-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure.↗

    PubMed lists PMID 41200852 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-12 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT07719933↗

    PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT06855758↗

    PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  11. Literature metadata

    Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.↗

    PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07304466↗

    PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  13. Clinical trials

    ClinicalTrials.gov record NCT04961528↗

    PeptideScanner retained ClinicalTrials.gov record NCT04961528 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  14. Clinical trials

    ClinicalTrials.gov record NCT06256432↗

    PeptideScanner retained ClinicalTrials.gov record NCT06256432 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  15. Literature metadata

    Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.↗

    PubMed lists PMID 23601499 in Liver international : official journal of the International Association for the Study of the Liver as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2013-04-21 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  16. Literature metadata

    Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation.↗

    PubMed lists PMID 26649801 in European journal of gastroenterology & hepatology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-03 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  17. Literature metadata

    A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock.↗

    PubMed lists PMID 27633962 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-10-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

5 records
  1. Literature metadata

    Terlipressin for hepatorenal syndrome.↗

    PubMed lists PMID 38353275 in Current opinion in gastroenterology as Review, Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.↗

    PubMed lists PMID 35838488 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-08-03 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.↗

    PubMed lists PMID 20306131 in International urology and nephrology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2010-03-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Terlipressin for hepatorenal syndrome.↗

    PubMed lists PMID 22972083 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.↗

    PubMed lists PMID 29943803 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2017-06-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

9 records
  1. Literature metadata

    Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.↗

    PubMed lists PMID 22322237 in Journal of hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-02-06 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    The Application of Terlipressin in the Management of Ascites in Liver Cirrhosis: Current Status and Prospects.↗

    PubMed lists PMID 39618221 in British journal of hospital medicine (London, England : 2005) as Journal Article, Review, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Formulary Drug Reviews: Terlipressin.↗

    PubMed lists PMID 38560548 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2023-01-26 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04460560↗

    PeptideScanner retained ClinicalTrials.gov record NCT04460560 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  5. Literature metadata

    Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.↗

    PubMed lists PMID 39295934 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-09-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT05242783↗

    PeptideScanner retained ClinicalTrials.gov record NCT05242783 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  7. Literature metadata

    TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW.↗

    PubMed lists PMID 37548701 in Shock (Augusta, Ga.) as Systematic Review, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.↗

    PubMed lists PMID 32574418 in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society as Journal Article, Review, with publication-date metadata of 2020-08-09 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Regulatory

    Federal Register notice 2024-03300↗

    The Federal Register published notice 2024-03300, attributed to FDA and its parent HHS department, on 2024-02-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin.↗

Source year

2023

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03572088↗

    PeptideScanner retained ClinicalTrials.gov record NCT03572088 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-22, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03822091↗

    PeptideScanner retained ClinicalTrials.gov record NCT03822091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-09, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04416282↗

    PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Source year

2022

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01143246↗

    PeptideScanner retained ClinicalTrials.gov record NCT01143246 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02770716↗

    PeptideScanner retained ClinicalTrials.gov record NCT02770716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  3. Regulatory

    Drugs@FDA application NDA022231↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 022231 with status AP dated 2022-09-14, and names terlipressin acetate among the application record's active ingredients.↗

  4. Literature metadata

    RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY.↗

    PubMed lists PMID 35442343 in Arquivos de gastroenterologia as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022 Jan-Mar (source-text precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03107091↗

    PeptideScanner retained ClinicalTrials.gov record NCT03107091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2021-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Literature metadata

    Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.↗

    PubMed lists PMID 32676484 in Canadian journal of gastroenterology & hepatology as Journal Article, Systematic Review, with publication-date metadata of 2020-06-22 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

4 records
  1. Literature metadata

    Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 31920672 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2019-12-23 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Federal Register notice 2020-14719↗

    The Federal Register published notice 2020-14719, attributed to FDA and its parent HHS department, on 2020-07-08. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04358016↗

    PeptideScanner retained ClinicalTrials.gov record NCT04358016 at 2026-11-15T21:47:40.408Z. Its registry update date was 2020-04-22, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  4. Literature metadata

    Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.↗

    PubMed lists PMID 30474439 in Current medical research and opinion as Journal Article, Review, with publication-date metadata of 2019-01-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2019

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03584087↗

    PeptideScanner retained ClinicalTrials.gov record NCT03584087 at 2026-11-15T21:47:40.408Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Literature metadata

    Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock.↗

    PubMed lists PMID 18683478 in Best practice & research. Clinical anaesthesiology as Journal Article, Review, with publication-date metadata of 2008-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2018

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03395574↗

    PeptideScanner retained ClinicalTrials.gov record NCT03395574 at 2026-11-15T21:47:40.408Z. Its registry update date was 2018-12-24, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Literature metadata

    Noradrenaline or terlipressin for hepatorenal syndrome?↗

    PubMed lists PMID 26334297 in Medwave as Comparative Study, Journal Article, Meta-Analysis, with publication-date metadata of 2015-08-27 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Comparison of 12-Hour with 72-Hour Terlipressin Therapy for Bleeding Esophageal Varices.↗

    PubMed lists PMID 28689520 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    [Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update].↗

    PubMed lists PMID 19950571 in Zhonghua yi xue za zhi as Journal Article, Meta-Analysis, with publication-date metadata of 2009-07-28 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.↗

    PubMed lists PMID 22075285 in European journal of internal medicine as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2017

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02588716↗

    PeptideScanner retained ClinicalTrials.gov record NCT02588716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-27, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02718599↗

    PeptideScanner retained ClinicalTrials.gov record NCT02718599 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-19, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00089570↗

    PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Source year

2016

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02059460↗

    PeptideScanner retained ClinicalTrials.gov record NCT02059460 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02757703↗

    PeptideScanner retained ClinicalTrials.gov record NCT02757703 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-05-03, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00628160↗

    PeptideScanner retained ClinicalTrials.gov record NCT00628160 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-02-24, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Source year

2015

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00986817↗

    PeptideScanner retained ClinicalTrials.gov record NCT00986817 at 2026-11-15T21:47:40.408Z. Its registry update date was 2015-06-15, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Source year

2012

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01637454↗

    PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01373606↗

    PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Source year

2008

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00369694↗

    PeptideScanner retained ClinicalTrials.gov record NCT00369694 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-09-25, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00370253↗

    PeptideScanner retained ClinicalTrials.gov record NCT00370253 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-04-11, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Source year

2006

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00115947↗

    PeptideScanner retained ClinicalTrials.gov record NCT00115947 at 2026-11-15T21:47:40.408Z. Its registry update date was 2006-03-09, and PeptideScanner's reviewed identity mapping was terlipressin.↗